{"id":"W4408853818","doi":"10.1038/s44276-025-00133-6","title":"A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers","year":2025,"lang":"en","type":"article","venue":"BJC Reports","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"FP7 Health; RECETOX Přírodovědecké Fakulty Masarykovy Univerzity; Takeda Oncology; Chugai Pharmaceutical; Bristol-Myers Squibb; Samsung; University of Oxford; Genentech; Cancer Research UK; Aptitude Health; Daiichi Sankyo Europe; Gilead Sciences; Servier; Queen's University; Merck KGaA; Ministerstvo Školství, Mládeže a Tělovýchovy; National Institute for Health and Care Research; Queen's University Belfast; Seagen; European Commission; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company; Associazione Italiana per la Ricerca sul Cancro; Les Laboratories Pierre Fabre; AstraZeneca","keywords":"Crizotinib; Tolerability; Medicine; Adverse effect; Internal medicine; Pharmacokinetics; Toxicity; Clinical trial; Oncology; Pharmacology; Colorectal cancer; ALK inhibitor; MEK inhibitor; Cancer; Lung cancer; Kinase; MAPK/ERK pathway; Chemistry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001471703,0.001914815,0.00216076,0.0005799971,0.0005346431,0.001130446,0.0009265088,0.0009485838,0.002435508],"category_scores_gemma":[0.0007036026,0.0007209408,0.001293821,0.0005784961,0.001144527,0.0007813054,0.0004202384,0.003253363,0.0009497051],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001423576,"about_ca_system_score_gemma":0.002012765,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002033305,"about_ca_topic_score_gemma":0.004099458,"domain_scores_codex":[0.9992844,0.0002693869,0.00004122735,0.0001429432,0.00008972505,0.0001722852],"domain_scores_gemma":[0.9993588,0.00004463896,0.0001058877,0.00005973923,0.00004074374,0.0003900963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5491614,0.1537382,0.01072261,0.0008361912,0.001628934,0.0007547639,0.0006492668,0.0041403,0.1554525,0.0003954493,0.004560347,0.11796],"study_design_scores_gemma":[0.3181939,0.6501323,0.01558422,0.00002873776,0.0004950572,0.0007307653,0.00008486684,0.001409996,0.01059157,0.0001336401,0.002576937,0.00003803763],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99328,0.00132877,0.0005774126,0.0002561826,0.0000703695,0.002398171,0.0005636266,0.0000994881,0.001426147],"genre_scores_gemma":[0.9936135,0.0008074631,0.001376571,0.0003311852,0.00007828514,0.001294762,0.001214005,0.00001836742,0.001265806],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002435508,"threshold_uncertainty_score":0.01032889,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.004268398584754407,"score_gpt":0.2552967227798368,"score_spread":0.2510283241950824,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}